Research Interests:

cancer pharmacology, drug target identification, therapeutic resistance, precision oncology

Highlighted Publications:

Jones, K., Keddy, C., Jenkins, C., Nicholson, K., Shinde, U., & Davare, M. A. (2024). Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain. Scientific Reports, 14(1), 22191. https://doi.org/10.1038/s41598-024-71687-7

Thawani, R., Repetto, M., Keddy, C., Nicholson, K., Jones, K., Nusser, K., Beach, C. Z., Harada, G., Drilon, A., & Davare, M. A. (2024). TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers. NPJ Precision Oncology, 8(1), 175. https://doi.org/10.1038/s41698-024-00663-1

Iyer, S. R., Nusser, K., Jones, K., Shinde, P., Keddy, C., Beach, C. Z., Aguero, E., Force, J., Shinde, U., & Davare, M. A. (2023). Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. EMBO Molecular Medicine, 15(10), e17367. https://doi.org/10.15252/emmm.202217367

Drilon, A., Horan, J. C., Tangpeerachaikul, A., Besse, B., Ou, S.-H. I., Gadgeel, S. M., Camidge, D. R., van der Wekken, A. J., Nguyen-Phuong, L., Acker, A., Keddy, C., Nicholson, K. S., Yoda, S., Mente, S., Sun, Y., Soglia, J. R., Kohl, N. E., Porter, J. R., Shair, M. D., … Lin, J. J. (2023). NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer Discovery, 13(3), 598–615. https://doi.org/10.1158/2159-8290.CD-22-0968

Keddy, C., Shinde, P., Jones, K., Kaech, S., Somwar, R., Shinde, U., & Davare, M. A. (2022). Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors. Molecular Cancer Therapeutics, 21(2), 336–346. https://doi.org/10.1158/1535-7163.MCT-21-0395

Keddy, C., Neff, T., Huan, J., Nickerson, J. P., Beach, C. Z., Akkari, Y., Ji, J., Moore, S., Nazemi, K. J., Corless, C. L., Beadling, C., Woltjer, R., Cho, Y.-J., Wood, M. D., & Davare, M. A. (2021). Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion. Cold Spring Harbor Molecular Case Studies, 7(5), a006109. https://doi.org/10.1101/mcs.a006109

Drilon, A., Jenkins, C., Iyer, S., Schoenfeld, A., Keddy, C., & Davare, M. A. (2021). ROS1-dependent cancers—Biology, diagnostics and therapeutics. Nature Reviews. Clinical Oncology, 18(1), 35–55. https://doi.org/10.1038/s41571-020-0408-9

The views and opinions expressed in this page are strictly those of the page author.

The contents of this page have not been reviewed or approved by the University of Minnesota.